The use of melatonin in the treatment of irritable bowel syndrome: a systematic review of randomized placebo-controlled clinical trials

Introduction. One of the most prevalent functional disorders of the gastrointestinal system, irritable bowel syndrome (IBS), significantly affects patients’ quality of life. At the moment, only symptomatic drugs are used to treat this disorder. Although using melatonin can be thought of as a form of pathogenetic therapy, its efficacy has not yet been conclusively demonstrated. This systematic review of randomized placebo controlled clinical trials reviews current data on the evaluation of the efficacy of melatonin in patients with IBS. Material and research methods. The search and selection of publications was carried out in the PubMed, ScienceDirect, ClinicalTrials.gov, Cochrane Library, eLibrary, medRxiv and International Clinical Trials Registry Platform databases from their publication until October 30, 2022. Results. The inclusion criteria were met by four randomized placebo-controlled trials, totaling 155 participants, and these trials were included in the subsequent analysis. All investigations revealed a considerable reduction in the frequency and severity of bloating, as well as a tendency for other intestinal symptoms to regress. Two trials reported an improvement in patients’ quality of life, albeit one of the studies did not find these changes to be statistically significant, and the other did not assess them. This review demonstrates that melatonin is effective in treating IBS by lowering the frequency and severity of the condition’s symptoms in the vast majority of published RCTs. The poor number and sample size of clinical trials, along with their inadequate methodological quality, prevent us from drawing any firm conclusions about the contribution of melatonin to the improvement of IBS patients’ quality of life. To confirm melatonin’s significance in the treatment of IBS patients, larger studies are required to assess its efficacy and safety when used in various doses.

melatonin, irritable bowel syndrome, randomized placebo-controlled clinical trials

1. Quigley E.M.M., Fried M., Gwee K. A., Khalif I., Hungin A. P.S., Lindberg G., et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome. Journal of Clinical Gastroenterology. 2016;50(9): 704-713. doi: 10.1097/MCG.0000000000000653.

2. Adriani A., Ribaldone D. G., Astegiano M., Durazzo M., Saracco G. M., Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Medica. 2018;60(4). doi: 10.23736/S0031-0808.18.03541-3.

3. Holtmann G.J., Ford A. C., Talley N. J. Pathophysiology of irritable bowel syndrome. The Lancet Gastroenterology & Hepatology. 2016;1(2): 133-146. doi: 10.1016/S2468-1253(16)30023-1.

4. Talley N.J., Holtmann G., Walker M. M. Therapeutic strategies for functional dyspepsia and irritable bowel syndrome based on pathophysiology. Journal of Gastroenterology. 2015;50(6): 601-613. doi: 10.1007/s00535-015-1076-x.

5. Chey W.D., Kurlander J., Eswaran S. Irritable Bowel Syndrome. JAMA. 2015;313(9): 949. doi: 10.1001/jama.2015.0954.

6. El-Salhy M. Irritable bowel syndrome: Diagnosis and pathogenesis. World Journal of Gastroenterology. 2012;18(37): 5151-5163. doi: 10.3748/wjg.v18.i37.5151.

7. Tanaka Y., Kanazawa M., Fukudo S., Drossman D. A. Biopsychosocial Model of Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility. 2011;17(2): 131-139. doi: 10.5056/jnm.2011.17.2.131.

8. Saito Y.A., Strege P. R., Tester D. J., Locke G. R., Talley N. J., Bernard C. E., et al. Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2009;296(2): G211-G218. doi: 10.1152/ajpgi.90571.2008.

9. Ford A.C., Quigley E. M.M., Lacy B.E, Lembo A. J., Saito Y. A., Schiller L. R., et al. Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. American Journal of Gastroenterology. 2014;109(10): 1547-1561. doi: 10.1038/ajg.2014.202.

10. Ringel-Kulka T., Choi C. H., Temas D., Kim A., Maier D. M., Scott K., et al. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. American Journal of Gastroenterology. 2015;110(9): 1339-1346. doi: 10.1038/ajg.2015.220.

11. Bajor A., Törnblom H., Rudling M., Ung K. A., Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut. 2015;64(1): 84-92. doi: 10.1136/gutjnl-2013-305965.

12. Zhen Y., Chu C., Zhou S., Qi M., Shu R. Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea. Molecular Medicine Reports. 2015;12(4): 5239-5245. doi: 10.3892/mmr.2015.4079.

13. Bertiaux-Vandaële N., Youmba S. B., Belmonte L., Lecleire S., Antonietti M., Gourcerol G., et al. The Expression and the Cellular Distribution of the Tight Junction Proteins Are Altered in Irritable Bowel Syndrome Patients With Differences According to the Disease Subtype. American Journal of Gastroenterology. 2011;106(12): 2165-2173. doi: 10.1038/ajg.2011.257.

14. Atkinson W., Lockhart S., Whorwell P. J., Keevil B., Houghton L. A. Altered 5-Hydroxytryptamine Signaling in Patients With Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2006;130(1): 34-43. doi: 10.1053/j.gastro.2005.09.031.

15. Ivashkin V.T., Maev I. V., Shelygin Yu.A. et аl. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74-95. (In Russ.) doi: 10.22416/1382-4376-2021-31-5-74-95.@@ Ивашкин В. Т., Маев И. В., Шелыгин Ю. А. и соавт. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74-95. doi: 10.22416/1382-4376-2021-31-5-74-95.

16. Ivashkin V.T., Poluektova E. A., Glazunov A. B., Putilovskiy M. A., Epstein O. I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterology. 2020;20(1): 2. doi: 10.1186/s12876-019-1143-5.

17. El-Salhy M., Hatlebakk J. G., Gilja O. H., Bråthen Kristoffersen A., Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5): 859-867. doi: 10.1136/gutjnl-2019-319630.

18. Ricci C., Rizzello F., Valerii M. C., Spisni E., Gionchetti P., Turroni S., et al. Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial. Nutrients. 2022;14(19): 4208. doi: 10.3390/nu14194208.

19. Ng Q.X., Soh A. Y. sen, Lim D. Y., Yeo W. Agomelatine, a novel therapeutic option for the management of irritable bowel syndrome. Journal of Clinical Pharmacy and Therapeutics. 2018;43(5): 752-756. doi: 10.1111/jcpt.12749.

20. Radwan P., Skrzydlo-Radomanska B., Radwan-Kwiatek K., Burak-Czapiuk B., Strzemecka J. Is melatonin involved in the irritable bowel syndrome? Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2009;60 Suppl 3: 67-70.

21. Storr M., Koppitz P., Sibaev A., Saur D., Kurjak M., Franck H., et al. Melatonin reduces non-adrenergic, non-cholinergic relaxant neurotransmission by inhibition of nitric oxide synthase activity in the gastrointestinal tract of rodents in vitro. Journal of Pineal Research. 2002;33(2): 101-108. doi: 10.1034/j.1600-079X.2002.02909.x.

22. Bubenik G.A., Dhanvantari S. Influence of Serotonin and Melatonin on Some Parameters of Gastrointestinal Activity. Journal of Pineal Research. 1989;7(4): 333-344. doi: 10.1111/j.1600-079X.1989.tb00909.x.

23. Hong F., Pan S., Xu P., Xue T., Wang J., Guo Y., et al. Melatonin Orchestrates Lipid Homeostasis through the Hepatointestinal Circadian Clock and Microbiota during Constant Light Exposure. Cells. 2020;9(2): 489. doi: 10.3390/cells9020489.

24. Park Y.S., Kim S. H., Park J. W., Kho Y., Seok P. R., Shin J. H., et al. Melatonin in the colon modulates intestinal microbiota in response to stress and sleep deprivation.Intestinal Research. 2020;18(3): 325-336. doi: 10.5217/ir.2019.00093.

25. Tarocco A., Caroccia N., Morciano G., Wieckowski M. R., Ancora G., Garani G., et al. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death & Disease. 2019;10(4): 317. doi: 10.1038/s41419-019-1556-7.

26. Gao T., Wang Z., Cao J., Dong Y., Chen Y. Melatonin alleviates oxidative stress in sleep deprived mice: Involvement of small intestinal mucosa injury.International Immunopharmacology. 2020;78: 106041. doi: 10.1016/j.intimp.2019.106041.

27. Tan D.X., Manchester L., Esteban-Zubero E., Zhou Z., Reiter R. Melatonin as a Potent and Inducible Endogenous Antioxidant: Synthesis and Metabolism. Molecules. 2015;20(10): 18886-18906. doi: 10.3390/molecules201018886.

28. Liu J., Clough S. J., Hutchinson A. J., Adamah-Biassi E.B., Popovska-Gorevski M., Dubocovich M. L. MT 1 and MT 2 Melatonin Receptors: A Therapeutic Perspective. Annual Review of Pharmacology and Toxicology. 2016;56(1): 361-383. doi: 10.1146/annurev-pharmtox-010814-124742.

29. Page M.J., McKenzie J.E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; n71. doi: 10.1136/bmj.n71.

30. Higgins J.P.T., Altman D. G., Gotzsche P. C., Juni P., Moher D., Oxman A. D., et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2): d5928-d5928. doi: 10.1136/bmj.d5928.

31. Scottish Intercollegiate Guidelines Network (SIGN). A guideline developer’s handbook. Edinburgh: SIGN; 2019. (SIGN publication no. 50). [November 2019]. Available from URL: http://www.sign.ac.uk.

32. Komarov F.I., Raĭkhlin N. T., Rapoport S. I. et al. Irritated bowel syndrome: clinicomorphological aspects of treatment with melaxen. Klinicheskaia meditsina. 2006; 84 (11): 30-36. (in Russ.)@@ Комаров Ф. И., Райхлин П. Т., Рапопорт С. И. и соавт. Синдром раздраженной кишки. Клиникоморфологические аспекты при лечении мелаксеном. Клиническая медицина. 2006; 84 (11): 30-36.

33. Haddaway N.R., Page M. J., Pritchard C. C., McGuinness L.A. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Systematic Reviews. 2022;18(2). doi: 10.1002/cl2.1230.

34. Song G. H. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54(10): 1402-1407. doi: 10.1136/gut.2004.062034.

35. Saha L., Malhotra S., Rana S., Bhasin D., Pandhi P. A Preliminary Study of Melatonin in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology. 2007;41(1): 29-32. doi: 10.1097/MCG.0b013e31802df84c.

36. Lu W.Z., Gwee K. A., Moochhalla S., Ho K. Y. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Alimentary Pharmacology and Therapeutics. 2005;22(10): 927-934. doi: 10.1111/j.1365-2036.2005.02673.x.

37. Chojnacki C., Walecka-Kapica E., Lokieć K., Pawłowicz M., Winczyk K., Chojnacki J., et al. Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women. Endokrynologia Polska. 2013;64(2): 114-120.

38. Srinivasan V., Pandi-Perumal S.R., Spence D. W., Moscovitch A., Trakht I., Brown G. M., et al. Potential use of melatonergic drugs in analgesia: Mechanisms of action. Brain Research Bulletin. 2010;81(4-5): 362-371. doi: 10.1016/j.brainresbull.2009.12.001.

39. Kasimay O., Cakir B., Devseren E., Yegen B. C. Exogenous melatonin delays gastric emptying rate in rats: role of CCK2 and 5-HT3 receptors. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2005;56(4): 543-553.